Asthma — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Asthma represents a multifaceted clinical syndrome characterized by variable airflow obstruction, bronchial hyperresponsiveness (BHR), and cellular inflammation. The Global Initiative for Asthma (GINA) defines asthma as a heterogeneous disease primarily marked by airway inflammation. The presence of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough, exhibiting variability over time and in intensity, alongside variable expiratory airflow limitation, constitutes the defining features of asthma. This condition results in fluctuating respiratory symptoms and variable airflow limitation, culminating in compromised activity levels, diminished quality of life, and occasional exacerbations, colloquially termed ‘asthma attacks.’ These exacerbations may necessitate emergency healthcare utilization and hospitalization and, in rare instances, lead to fatalities. Asthma’s risk factors encompass genetic, environmental, and host-related elements. While a family history of asthma is common, it is neither sufficient nor necessary for asthma development. Clinical categorization of asthma involves classifying it as mild intermittent, mild persistent, moderate persistent, or severe persistent based on symptom frequency, severity, and lung function assessed through forced expiratory volume in 1 second (FEV1). Asthma manifests in various types, including allergic asthma, aspirin-induced asthma, cough-variant asthma, exercise-induced asthma, nighttime asthma, steroid-resistant asthma, and occupational asthma. Asthma is frequently associated with comorbidities that can impact its clinical expression, with rhinitis, sinusitis, gastroesophageal reflux disease (GERD), obstructive sleep apnea (OSA), hormonal disorders, and psychopathologies reported as common contributing conditions. Although the specific influence of these comorbidities is yet to be fully characterized, their presence is noteworthy. Additionally, other conditions, sometimes unrelated to asthma, exhibit high prevalence among asthmatic patients. The pharmacological management of asthma involves several major drug classes, including bronchodilators (beta-2 agonists, anticholinergics), corticosteroids, leukotriene modifiers, mast cell stabilizers, methylxanthines, and immunomodulators. These drugs can be administered through inhalation, oral ingestion, or subcutaneous and intravenous injection, with inhaled forms available in aerosolized and powdered formulations.
· In the United States, over 27 million individuals are affected by asthma, with a higher prevalence among male children compared to their female counterparts. Approximately 7% of male children and 5.4% of female children experience asthma.
Thelansis’s “Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Asthma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Asthma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Asthma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Tags: Asthma, Asthma market outlook, Asthma competitive landscape, Asthma market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)
